HC Wainwright Weighs in on BioAtla FY2024 Earnings

BioAtla, Inc. (NASDAQ:BCAB) – Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for BioAtla in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($1.46) for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. The firm had revenue of $11.00 million during the quarter. During the same period last year, the firm earned ($0.70) EPS.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of BioAtla in a research note on Monday, September 16th.

BioAtla Stock Performance

BCAB stock opened at $1.56 on Friday. The firm has a market cap of $75.40 million, a P/E ratio of -0.92 and a beta of 1.03. The firm’s fifty day moving average is $1.91 and its 200 day moving average is $1.87. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02.

Hedge Funds Weigh In On BioAtla

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its stake in shares of BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after purchasing an additional 10,384 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of BioAtla by 5.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after buying an additional 28,133 shares during the period. GSA Capital Partners LLP bought a new position in shares of BioAtla during the third quarter valued at approximately $623,000. Chicago Partners Investment Group LLC purchased a new stake in BioAtla in the third quarter worth $44,000. Finally, Vontobel Holding Ltd. bought a new stake in BioAtla in the third quarter valued at $28,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.